(PDF) mTOR Inhibitors Control the Growth of EGFR Mutant

mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even After Acquiring Resistance by HGF

PLoS ONE - United States

doi 10.1371/journal.pone.0062104

Full Text

Open PDF

Abstract

Available in full text

Date

May 14, 2013

Authors

Publisher

Public Library of Science (PLoS)

Related search

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

Journal of Thoracic Oncology

English

Reverse of EGFR Inhibitors Resistance by Co-Delivering EGFR and Integrin Αvβ3 Inhibitors With Nanoparticles in Non-Small Cell Lung Cancer

English

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

English

HGF Induces Novel EGFR Functions Involved in Resistance Formation to Tyrosine Kinase Inhibitors

English

Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)

English

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

English

WZ4002, a Third-Generation EGFR Inhibitor, Can Overcome Anoikis Resistance in EGFR-mutant Lung Adenocarcinomas More Efficiently Than SRC Inhibitors

Laboratory Investigation

English

Cranial Irradiation for Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors

English

AXL/epidermal Growth Factor Receptor (EGFR) Complexes in Breast Cancer - Culprits for Resistance to EGFR Inhibitors?

Breast Cancer Research

Cancer Research

Oncology

2013

English

Amanote Research

mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even After Acquiring Resistance by HGF

PLoS ONE - United States

doi 10.1371/journal.pone.0062104

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

Reverse of EGFR Inhibitors Resistance by Co-Delivering EGFR and Integrin Αvβ3 Inhibitors With Nanoparticles in Non-Small Cell Lung Cancer

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

HGF Induces Novel EGFR Functions Involved in Resistance Formation to Tyrosine Kinase Inhibitors

Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

WZ4002, a Third-Generation EGFR Inhibitor, Can Overcome Anoikis Resistance in EGFR-mutant Lung Adenocarcinomas More Efficiently Than SRC Inhibitors

Cranial Irradiation for Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors

AXL/epidermal Growth Factor Receptor (EGFR) Complexes in Breast Cancer - Culprits for Resistance to EGFR Inhibitors?